Alliancebernstein L.P. Grows Position in DexCom, Inc. (NASDAQ:DXCM)

Alliancebernstein L.P. lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 24.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 555,164 shares of the medical device company’s stock after purchasing an additional 107,916 shares during the quarter. Alliancebernstein L.P.’s holdings in DexCom were worth $43,175,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Versant Capital Management Inc purchased a new position in DexCom in the fourth quarter valued at $25,000. Private Trust Co. NA grew its position in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 245 shares during the period. TD Private Client Wealth LLC grew its position in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 167 shares during the period. Larson Financial Group LLC increased its stake in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new position in DexCom during the fourth quarter worth approximately $38,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Morgan Stanley boosted their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Finally, Citigroup raised their price target on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $99.82.

Insider Buying and Selling

In other news, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares in the company, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 105,009 shares of company stock worth $8,044,178. Insiders own 0.30% of the company’s stock.

DexCom Price Performance

DXCM stock opened at $59.83 on Friday. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $141.99. The firm has a market capitalization of $23.46 billion, a PE ratio of 41.84, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The business has a 50 day simple moving average of $80.14 and a 200-day simple moving average of $76.92.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.